These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 25469008)
1. Recent applications of chemosensitivity tests for colorectal cancer treatment. Yoon YS; Kim JC World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008 [TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
3. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577 [TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. Kubo A; Hashimoto H; Takahashi N; Yamada Y World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634 [TBL] [Abstract][Full Text] [Related]
6. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer. Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936 [TBL] [Abstract][Full Text] [Related]
7. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Dienstmann R; Salazar R; Tabernero J Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065 [TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276 [TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Coppedè F; Lopomo A; Spisni R; Migliore L World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767 [TBL] [Abstract][Full Text] [Related]
10. Current trends in clinical genetics of colorectal cancer. Markovic S; Dimitrijevic I; Zogovic B; Markovic V; Barisic G; Krivokapic Z J BUON; 2016; 21(5):1042-1049. PubMed ID: 27837603 [TBL] [Abstract][Full Text] [Related]
11. Cetuximab in the treatment of patients with colorectal cancer. Garrett CR; Eng C Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053 [TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer: from prevention to personalized medicine. Binefa G; Rodríguez-Moranta F; Teule A; Medina-Hayas M World J Gastroenterol; 2014 Jun; 20(22):6786-808. PubMed ID: 24944469 [TBL] [Abstract][Full Text] [Related]
15. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S J BUON; 2013; 18(1):116-23. PubMed ID: 23613396 [TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
17. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222 [TBL] [Abstract][Full Text] [Related]
18. Personalized treatment for patients with colorectal cancer: role of biomarkers. Duffy MJ Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. De Mattia E; Cecchin E; Toffoli G Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]